Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus AMINOSYN II 8 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus AMINOSYN II 8 5.
AMINOSYN 3.5% M IN PLASTIC CONTAINER vs AMINOSYN II 8.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a mixture of essential and non-essential amino acids used for parenteral nutrition. It provides substrates for protein synthesis, thereby maintaining nitrogen balance and supporting tissue repair and growth.
Aminosyn II 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis when administered intravenously. It serves as a substrate for protein metabolism, promoting nitrogen retention and tissue repair.
Intravenous infusion: 500 mL to 1 L of 3.5% amino acid solution per day for adults; rate not to exceed 0.1 g amino acids/kg/hr.
Intravenous infusion, typical adult dose is 1.0 to 1.5 g amino acids/kg/day, administered as part of total parenteral nutrition; rate not to exceed 0.1 g amino acids/kg/hour.
None Documented
None Documented
Variable (minutes to hours) due to rapid metabolic utilization; terminal half-life in plasma is <10 minutes for most amino acids.
Variable; individual amino acids have half-lives ranging from minutes to hours. Clinical context: infusion rate and metabolic demand determine steady-state levels.
Renal: >90% as amino acids and metabolites; negligible biliary/fecal elimination.
Amino acids are primarily eliminated via metabolism; less than 10% is excreted renally as free amino acids. No significant biliary or fecal excretion.
Category C
Category C
Amino Acid Solution
Amino Acid Solution